Monitor proxy vote outcome on June 9; DOMA's 3 nominees are unlikely to gain seats given management's shareholder outreach (97.4% of shares contacted) and recent operational momentum. If DOMA loses, near-term stability supports the stock; a surprise win would introduce strategic uncertainty.
Price Chart
Executive Summary
Pacira BioSciences issued a DEFA14A letter to stockholders ahead of its June 9, 2026 Annual Meeting, urging support for its three board nominees and rebutting activist DOMA Perpetual's proxy contest. The letter highlights record 2025 revenue of $726.4M, GAAP net income of $7.0M ($0.16/share), and EXPAREL volume growth of 6.2%, while arguing DOMA's nominees lack relevant experience.
Key Facts
- Annual Meeting scheduled for June 9, 2026; three board seats contested by DOMA Perpetual nominees.
- Pacira reports 2025 record total revenues of $726.4M and GAAP net income of $7.0M ($0.16 per share).
- EXPAREL year-over-year volume growth of 6.2% in 2025, accelerating to 8% in H2 2025.
- Management and board have met with DOMA 17 times since September 2023 but determined its nominees lack relevant experience.
- Stock price up ~31% since announcement of 5x30 strategy (Jan 2025 to May 2026).
- EXPREL settlement provides full exclusivity into 2030 with gradual capped transition through 2039.
Financial Impact
Record $726.4M revenue and $7.0M GAAP net income in 2025
Risk Factors
- Activist proxy contest could distract management or force suboptimal capital allocation changes.
- EXPAREL volume growth, while improving, remains below 10% annual target.
- Patent litigation over EXPAREL could re-emerge despite recent settlement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-038528 |
| Document: 0001628280-26-038528-index-headers.html | 0001628280-26-038528 |
| Document: 0001628280-26-038528-index.html | 0001628280-26-038528 |
| Document: 0001628280-26-038528.txt | 0001628280-26-038528 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $25.21 (−1.45%) |
Jul 22, 2026 10w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $25.21 (−1.48%) |
Jun 30, 2026 13w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $25.21 (−0.63%) |
Jun 13, 2026 15w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $25.21 (+10.86%) |
Jun 4, 2026 17w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $25.21 (+10.81%) |
Jun 4, 2026 17w ago | 144 | $22.67 $25.39 | ▲ +12.00% | ▲ +13.37% | $25.21 (+11.20%) |
Jun 1, 2026 17w ago | DEFA14A | $22.25 $25.03 | ▲ +12.49% | ▲ +14.06% | $25.21 (+13.30%) |
May 27, 2026 18w ago | DEFA14A | $23.68 $25.24 | ▲ +6.59% | ▲ +9.73% | $25.21 (+6.46%) |
May 26, 2026 18w ago | DEFA14A | $24.04 $24.37 | ▲ +1.37% | ▲ +3.27% | $25.21 (+4.87%) |
May 20, 2026 19w ago | DEFA14A | $23.48 $22.72 | ▼ −3.24% | ▼ −3.57% | $25.21 (+7.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access